Co-targeting of two receptors or ligands that are involved in modulating a patient’s immune system via a single molecular format provides advantages over the co-administration of two biologics. At Shattuck Labs, we have pioneered the development of bifunctional Fc-based fusion protein technologies that are designed to have potential therapeutic applications in oncology and autoimmunity. In this webinar, our expert speaker will describe the concept behind the fusion protein technology and how ThermoFisher Scientific’s GeneArt protein production service has been integrated into the preclinical workflow during the startup stage and evolution of Shattuck Labs’ R&D function.
Attend this webinar to learn about:
- The principles of bifunctional fusion protein design
- The value of incorporating transient protein production for candidate screening and lead selection
- How to generate a preclinical data package to support an investigational new drug filing
